Open AccessMaraviroc (Celsentri) in HIV treatment
Author(s) -
Viola Sacchi
Publication year - 2008
Publication title -
farmeconomia health economics and therapeutic pathways
Language(s) - English
Resource type - Journals
eISSN - 1721-6923
pISSN - 1721-6915
DOI - 10.7175/fe.v9i4.239
Subject(s) - maraviroc , reverse transcriptase , ccr5 receptor antagonist , medicine , virology , nucleoside reverse transcriptase inhibitor , integrase inhibitor , integrase , human immunodeficiency virus (hiv) , protease , protease inhibitor (pharmacology) , pharmacology , antiretroviral therapy , immunology , biology , viral load , chemokine receptor , enzyme , inflammation , rna , biochemistry , chemokine , gene
Since 1996, the prognosis of people living with immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) has improved significantly, due to highly active antiretroviral therapies (HAART) based on a combination of 3-4 anti-HIV drugs; the use of these drugs can achieve a durable suppression of HIV viraemia, turning HIV infection into a chronic illness. The three first licensed classes of antiretroviral agents are nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs). Until recently, treatment options for individuals developing resistance to these drugs have been limited, but new drugs in existing classes (second generation NNRTIs and novel PIs) and novel classes of drugs (integrase inhibitors, CCR5 antagonists and fusion inhibitors) have become clinically available
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom